Browse articles from EyeWorld.org related to gene therapy. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ ‘Visionary Report’ sheds light on understanding, perspectives of AMD
➤ NDA submitted for Demodex blepharitis treatment
➤ Study complete for trial of oral diabetic retinopathy therapy
➤ Enrollment complete for study comparing dry eye therapeutic device to cyclosporine
➤ Gene therapy developed for ciliopathy associated with a form of Leber congenital amaurosis
➤ ASCRS news and events
➤ Two-year results from Phase 3 study for GA therapy
➤ BLA resubmission for bevacizumab
➤ Strategic licensing for pharmacologic treatment for keratoconus
➤ Study: Gene therapy restores some cone function to otherwise colorblind children
➤ ASCRS news and events
➤ Small-aperture IOL receives FDA approval
➤ First patient enrolled in new LASIK trial
➤ Safety of sustained-release intravitreal implant confirmed
➤ Dosing complete in Phase 1/2a trial for injectable wet AMD therapy
➤ First patient dosed in light-activated optogenetic monotherapy study
➤ Phase 2 study for investigational new immunomodulator to treat dry eye disease
➤ Partnership created to develop tissue implant therapies
➤ ASCRS news and events
➤ Nerve growth factor being studied as a possible treatment for Sjogren’s-related dry eye
➤ Investigational RNA therapy doesn’t meet primary endpoint
➤ Phase 1 clinical trial for bioerodible, sustained anti-VEGF delivery
➤ Positive interim data for diabetic retinopathy treatment
➤ Positive results in trial for high-dose aflibercept
➤ Additional Phase 3 trial data for Beovu in DME
➤ ASCRS news and events
➤ FDA clearance for viscodelivery system
➤ FDA approves IND application for immunomodulatory agent for dry eye
➤ Phase 2b results for sustained-release, IOP-lowering implant
➤ Positive topline Phase 2 results for investigational dry eye drug
➤ Phase 2 trials begin for two transdermal drug formulations
➤ Second pivotal trial begins for wet AMD gene therapy
➤ Alcon completes acquisition of Ivantis
➤ ASCRS news and events
➤ Small-aperture IOL receives approvable letter from the FDA
➤ Topline results from Phase 2 clinical trial for intracanalicular insert for treatment of dry eye disease
➤ First in-human study to target biomarkers in the eye that identify ALS
➤ Study provides better understanding for bilateral effect after unilateral injection of gene therapy
➤ ASCRS news and events
➤ Positive topline results from Phase 3 trial for first-in-class dry eye drop
➤ Study: Long-term efficacy of neuromyelitis optica spectrum disorder treatment
➤ Long-term data from gene therapy injection for wet AMD
➤ Positive data from Phase 1/2 trial of gene therapy for geographic atrophy
➤ Ophthalmic device company partners with augmented reality tech company
➤ New and updated products for cataract workflow announced
➤ FDA approves first biosimilar in ophthalmology
➤ Acquisition of gene therapy company
➤ Licensing agreement for compounds targeting Demodex mites
➤ ASCRS news and events
➤ Orphan drug designation granted for retinitis pigmentosa treatment
➤ Licensing agreement for progressive myopia treatment
➤ Study: Gene editing prevents Fuchs in mice
➤ Enrollment complete for Phase 3 program evaluating anti-inflammatory, immunomodulation drug for DED
➤ ASCRS news and events
➤ Investigational gene therapy for choroideremia does not meet study endpoints
➤ Positive safety results in Phase 1/2a clinical trial of investigational drug for wet AMD
➤ Patient enrollment complete for Phase 3 clinical trial of sustained-release travoprost implant
➤ Two companies enter collaboration to develop, commercialize ocular surface disease therapies
➤ ASCRS events
